{"cik":1540171,"taxonomy":"us-gaap","tag":"LiabilitiesCurrent","label":"Liabilities, Current","description":"Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.","entityName":"Avalyn Pharma Inc.","units":{"USD":[{"end":"2025-12-31","val":14091000,"accn":"0001193125-26-254623","fy":2026,"fp":"Q1","form":"10-Q","filed":"2026-06-03"},{"end":"2025-12-31","val":14091000,"accn":"0001193125-26-345820","fy":2026,"fp":"Q2","form":"10-Q","filed":"2026-08-12"},{"end":"2025-12-31","val":14091000,"accn":"0001193125-26-457071","fy":2026,"fp":"Q3","form":"10-Q","filed":"2026-11-12","frame":"CY2025Q4I"},{"end":"2026-03-31","val":11787000,"accn":"0001193125-26-254623","fy":2026,"fp":"Q1","form":"10-Q","filed":"2026-06-03","frame":"CY2026Q1I"},{"end":"2026-06-30","val":10809000,"accn":"0001193125-26-345820","fy":2026,"fp":"Q2","form":"10-Q","filed":"2026-08-12","frame":"CY2026Q2I"},{"end":"2026-09-30","val":12955000,"accn":"0001193125-26-457071","fy":2026,"fp":"Q3","form":"10-Q","filed":"2026-11-12","frame":"CY2026Q3I"}]}}